Omeros Corporation (NASDAQ:OMER) Given Average Rating of “Moderate Buy” by Brokerages

Omeros Corporation (NASDAQ:OMER) has received an average recommendation of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $18.00.

Several research analysts recently weighed in on OMER shares. D. Boral Capital restated a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Wednesday, September 3rd. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Omeros in a report on Friday, June 27th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a report on Friday, August 15th. Finally, Wall Street Zen upgraded Omeros from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th.

Omeros Price Performance

Shares of NASDAQ:OMER opened at $4.10 on Wednesday. The business’s 50 day moving average price is $4.14 and its 200-day moving average price is $4.81. Omeros has a 1 year low of $2.95 and a 1 year high of $13.60. The firm has a market capitalization of $279.05 million, a price-to-earnings ratio of -1.94 and a beta of 2.37.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.02. The company had revenue of $28.60 million during the quarter, compared to analysts’ expectations of $0.31 million. On average, sell-side analysts expect that Omeros will post -3.09 earnings per share for the current year.

Institutional Investors Weigh In On Omeros

Several institutional investors and hedge funds have recently added to or reduced their stakes in OMER. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Omeros in the first quarter valued at about $579,000. GAMMA Investing LLC raised its holdings in shares of Omeros by 14,486.3% in the 1st quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 7,388 shares during the period. Hsbc Holdings PLC acquired a new stake in shares of Omeros during the first quarter worth about $142,000. Deutsche Bank AG grew its stake in shares of Omeros by 38.2% in the fourth quarter. Deutsche Bank AG now owns 40,046 shares of the biopharmaceutical company’s stock worth $396,000 after acquiring an additional 11,068 shares in the last quarter. Finally, Sowell Financial Services LLC purchased a new stake in Omeros during the 1st quarter worth about $88,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.